- Trials with a EudraCT protocol (56)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
56 result(s) found for: MicroRNA.
Displaying page 1 of 3.
EudraCT Number: 2015-002755-94 | Sponsor Protocol Number: CV185-391 | Start Date*: 2016-07-26 | |||||||||||
Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE | |||||||||||||
Full Title: MicroRNAs and target genes modulation in subjects with atrial fibrillation treated with apixaban or warfarin | |||||||||||||
Medical condition: Atrial fibrillation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003413-10 | Sponsor Protocol Number: ACDHUVV-16 | Start Date*: 2016-12-20 |
Sponsor Name:FIMABIS | ||
Full Title: MicroRNAs expression analysis in patients undergoing cardiac surgery treated with halogenated anesthetics. Identification of microRNAs related to the cardioprotective effect | ||
Medical condition: Cardiac surgery | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2014-001563-12 | Sponsor Protocol Number: 20142017 | Start Date*: 2015-02-16 |
Sponsor Name:University Medical Center Groningen | ||
Full Title: Efficacy of Single inhaler Maintenance And Reliever Therapy (SMART) with Spiromax® budesonide/formoterol versus fixed dose treatment with Diskus® fluticasone/salmeterol in COPD | ||
Medical condition: Chronic obstructive pulmonary disease (COPD) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2021-005401-28 | Sponsor Protocol Number: AOI2021ME_PICKERING | Start Date*: 2022-01-26 |
Sponsor Name:University Hospital of Clermont-Ferrand | ||
Full Title: Effects of the combination of magnesium bisphosphonates versus bisphosphonates alone on bone remodeling: Randomized pilot clinical trial | ||
Medical condition: postmenopausal osteoporosis | ||
Disease: | ||
Population Age: Elderly | Gender: Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-005310-17 | Sponsor Protocol Number: CAMG334AIT05T | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:ASL 1 AVEZZANO-SULMONA-L'AQUILA | |||||||||||||
Full Title: MicroRNA profile in women with migraine before and after treatment with erenumab | |||||||||||||
Medical condition: Episodic or chronic migraine | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-001856-51 | Sponsor Protocol Number: 12.007 | Start Date*: 2014-08-26 | |||||||||||
Sponsor Name:Aleksander Krag | |||||||||||||
Full Title: Anti-fibrotic and molecular aspects of rifaximin in alcoholic liver disease: A randomized placebo controlled clinical trial | |||||||||||||
Medical condition: Liver fibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001173-69 | Sponsor Protocol Number: 126496 | Start Date*: 2020-10-22 | |||||||||||
Sponsor Name:Pernille Ravn | |||||||||||||
Full Title: Impact of LTBI treatment on glucose tolerance and chronic inflammation | |||||||||||||
Medical condition: latent tuberculosis infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-002519-14 | Sponsor Protocol Number: 2015-775 | Start Date*: 2015-08-25 | |||||||||||
Sponsor Name:Herlev Hospital | |||||||||||||
Full Title: The MIRAD study - Mineralocorticoid Receptor Antagonists in Type 2 Diabetes. A randomised, double-blind, placebo-controlled study of the effect of Mineralocorticoid Receptor Antagonists in Type 2 D... | |||||||||||||
Medical condition: diabetes (type 2) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000188-25 | Sponsor Protocol Number: LoveMi | Start Date*: 2013-10-23 |
Sponsor Name:Charité - Universitätsmedizin Berlin | ||
Full Title: Lormetazepam versus Midazolam used as sedatives for critically ill patients. | ||
Medical condition: Sedation | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-005147-14 | Sponsor Protocol Number: DEDiCa | Start Date*: 2016-03-16 | ||||||||||||||||
Sponsor Name:ISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE | ||||||||||||||||||
Full Title: The effect of low dietary glycemic index, excercise and vitamin D on breast cancer recurrence in women | ||||||||||||||||||
Medical condition: female breast cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
Trial protocol: IT (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003036-20 | Sponsor Protocol Number: 1-2016 | Start Date*: 2017-10-02 | |||||||||||
Sponsor Name:FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI" | |||||||||||||
Full Title: A randomized trial of multifactorial primary prevention in high risk subjects candidate to a lung cancer early detection CT program | |||||||||||||
Medical condition: health subjects (multifactorial primary prevention) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-004854-46 | Sponsor Protocol Number: 1333 | Start Date*: 2014-04-04 | |||||||||||
Sponsor Name:Herlev University Hospital | |||||||||||||
Full Title: Randomized 1. Line treatment with gemcitabine, capecitabine, oxaliplatin vs gemcitabin and cisplatin to patients with cholangiocarcinoma. | |||||||||||||
Medical condition: patient with metastatic cholangiocarcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-001559-11 | Sponsor Protocol Number: 1312 | Start Date*: 2013-09-13 | |||||||||||
Sponsor Name:Herlev University Hospital | |||||||||||||
Full Title: Chemotherapy with gemcitabine, capecitabine, irinotecan and bevacizumab to patients with cholangiocarcinoma after progression on first line treatment. | |||||||||||||
Medical condition: patients with cholangiocarcinoma after progression. When patients with cholangiocarcinoma cannot be operated, we cannot cure them. The purpose of oncologic treatment is to prolong survival and to e... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002222-37 | Sponsor Protocol Number: 1626 | Start Date*: 2016-09-07 | |||||||||||
Sponsor Name:Herlev og Gentofte Hospital | |||||||||||||
Full Title: A randomized phase II study between regorafenib and continuing biologic treatment to multi treated patients with colorectal cancer. | |||||||||||||
Medical condition: Patient with metastatic colorectal cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-020188-19 | Sponsor Protocol Number: 1003 | Start Date*: 2010-09-24 | |||||||||||
Sponsor Name:Oncology Department | |||||||||||||
Full Title: Intra-hepatic chemotherapy with oxaliplatin every second week in combination with systemic gemcitabine and capecitabine and in patients with a KRAS-wild type tumour in combination with cetuximab in... | |||||||||||||
Medical condition: Patient with non-resectable liver metastases from cholangiocarcinoma. A phase II trial. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-000273-31 | Sponsor Protocol Number: AA1023 | Start Date*: 2011-04-18 | |||||||||||
Sponsor Name:Herlev University Hospital | |||||||||||||
Full Title: Intra-hepatic and systemic chemotherapy with or without antibody for patients with non-resectable liver metastasis from solid tumours | |||||||||||||
Medical condition: Intra-hepatic and systemic chemotherapy with or without antibody for patients with non-resectable liver metastasis from solid tumours | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-004686-28 | Sponsor Protocol Number: 14143JK-AS | Start Date*: 2018-07-16 |
Sponsor Name:Belfast Health and Social Care Trust (BHSCT) | ||
Full Title: A randomised, double-blind, placebo-controlled trial to evaluate the effect of Epstein-Barr virus suppression in chronic obstructive pulmonary disease (EViSCO trial). | ||
Medical condition: Epstein-Barr virus infection in patients with chronic obstructive pulmonary disease. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2010-018770-20 | Sponsor Protocol Number: DC-005 | Start Date*: 2010-05-21 |
Sponsor Name:Oslo University Hospital | ||
Full Title: Phase I/II trial of vaccine therapy in curative resected prostate cancer patients using autologous dendritic cells loaded with mRNA from primary prostate cancer tissue, hTERT and surviving. | ||
Medical condition: Prostatic cancer patients who have received curative surgery. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: NO (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2012-002940-26 | Sponsor Protocol Number: 212082PCR3011 | Start Date*: 2013-05-24 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Randomized, Double-blind, Comparative Study of Abiraterone Acetate Plus Low-dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Subjects With High-Risk, Me... | |||||||||||||
Medical condition: Metastatic Hormone-Naive Prostate Cancer (mHNPC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) CZ (Completed) FR (Completed) SE (Completed) HU (Completed) PT (Completed) FI (Completed) ES (Completed) IT (Completed) SK (Completed) DK (Completed) DE (Completed) BE (Completed) PL (Completed) BG (Completed) NL (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-004846-31 | Sponsor Protocol Number: 386022010017 | Start Date*: 2017-12-14 | |||||||||||
Sponsor Name:University medical centre Maribor | |||||||||||||
Full Title: Impact of vitamin D supplementation in patients with multiple sclerosis | |||||||||||||
Medical condition: Relapsing remitting multiple sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SI (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
